Immunotherapy for lung cancers

Journal of Biomedicine and Biotechnology

Volumn 2011, Issue , 2011, Pages

  Sun, Kuang Hui ^a,c   Ho, Ming Yi ^a   Tang, Shye Jye ^b   Yang, Winnie ^c  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN OCEAN UNIVERSITY   (Taiwan)

^c TAIPEI CITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AGATOLIMOD; ANTIIDIOTYPIC ANTIBODY; ANTINEOPLASTIC AGENT; BCG VACCINE; BLP25 LIPOSOME VACCINE; CANCER VACCINE; CARBOPLATIN; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; FAS LIGAND; FLUDARABINE; GANGLIOSIDE ANTIBODY; GEFITINIB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; INTERLEUKIN 2; LENALIDOMIDE; MELANOMA ANTIGEN 3; PACLITAXEL; PHOSPHORYL LIPID A; PLACEBO; PLATINUM; QS 21; RECOMBINANT EPIDERMAL GROWTH FACTOR; TAXANE DERIVATIVE; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADAPTIVE IMMUNITY; ADVANCED CANCER; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL KILLING; CYTOTOXIC T LYMPHOCYTE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; IMMUNE EVASION; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOCYTE ACTIVATION; METASTASIS; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REGULATORY T LYMPHOCYTE; REVIEW; SOLID TUMOR; SUPPRESSOR CELL; TH2 CELL; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR REGRESSION; ARTICLE; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOTHERAPY; LUNG TUMOR; TUMOR ESCAPE;

ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; LUNG NEOPLASMS; TUMOR ESCAPE;

EID: 79953290309     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2011/250860     Document Type: Review

References (101)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M. J., Cancer statistics, 2007 Ca-A Cancer Journal for Clinicians 2007 57 1 43 66 (Pubitemid 46148091)
2. Mountain C. F., Staging classification of lung cancer: a critical evaluation Clinics in Chest Medicine 2002 23 1 103 121 (Pubitemid 34207765)
3. Cersosimo R. J., Lung cancer: a review American Journal of Health-System Pharmacy 2002 59 7 611 642 (Pubitemid 34279366)
4. Pardoll D., Allison J., Cancer immunotherapy: breaking the barriers to harvest the crop Nature Medicine 2004 10 9 887 892 (Pubitemid 39273721)
5. Gross S., Walden P., Immunosuppressive mechanisms in human tumors: why we still cannot cure cancer Immunology Letters 2008 116 1 7 14
6. Dunn G. P., Old L. J., Schreiber R. D., The immunobiology of cancer immunosurveillance and immunoediting Immunity 2004 21 2 137 148 (Pubitemid 39094044)
7. Diefenbach A., Raulet D. H., The innate immune response to tumors and its role in the induction of T-cell immunity Immunological Reviews 2002 188 9 21 (Pubitemid 35398861)
8. Nouri-Shirazi M., Banchereau J., Fay J., Palucka K., Dendritic cell based tumor vaccines Immunology Letters 2000 74 1 5 10
9. Lord E. M., Frelinger J. G., Tumor immunotherapy: cytokines and antigen presentation Cancer Immunology Immunotherapy 1998 46 2 75 81 (Pubitemid 28177481)
10. Shurin M. R., Lu L., Kalinski P., Stewart-Akers A. M., Lotze M. T., Th1/Th2 balance in cancer, transplantation and pregnancy Springer Seminars in Immunopathology 1999 21 3 339 359 (Pubitemid 30011443)
11. Nishimura T., Iwakabe K., Sekimoto M., Ohmi Y., Yahata T., Nakui M., Sato T., Habu S., Tashiro H., Sato M., Ohta A., Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo Journal of Experimental Medicine 1999 190 5 617 627 (Pubitemid 29428646)
12. Shurin M. R., Lu L., Kalinski P., Stewart-Akers A. M., Lotze M. T., Th1/Th2 balance in cancer, transplantation and pregnancy Springer Seminars in Immunopathology 1999 21 3 339 359 (Pubitemid 30011443)
13. Wei H., Sun R., Xiao W., Feng J., Zhen C., Xu X., Tian Z., Type two cytokines predominance of human lung cancer and its reverse by traditional Chinese medicine TTMP Cellular amp; Molecular Immunology 2004 1 1 63 70
14. Yoshimura A., Signal transduction of inflammatory cytokines and tumor development Cancer Science 2006 97 6 439 447 (Pubitemid 43811583)
15. Titu L. V., Monson J. R., Greenman J., The role of CD8 + T cells in immune responses to colorectal cancer Cancer Immunology, Immunotherapy 2002 51 5 235 247 (Pubitemid 34810704)
16. Carlos T. M., Leukocyte recruitment at sites of tumor: dissonant orchestration Journal of Leukocyte Biology 2001 70 2 171 184 (Pubitemid 32751507)
17. Subleski J. J., Wiltrout R. H., Weiss J. M., Application of tissue-specific NK and NKT cell activity for tumor immunotherapy Journal of Autoimmunity 2009 33 3-4 275 281
18. Cerwenka A., Lanier L. L., Natural killer cells, viruses and cancer Nature Reviews Immunology 2001 1 1 41 49 (Pubitemid 33741974)
19. Hayakawa Y., Kelly J. M., Westwood J. A., Darcy P. K., Diefenbach A., Raulet D., Smyth M. J., Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin Journal of Immunology 2002 169 10 5377 5381 (Pubitemid 35291630)
20. Fehniger T. A., Cai S. F., Cao X., Bredemeyer A. J., Presti R. M., French A., Ley T. J., Acquisition of murine NK cell cytotoxicity requires the translation of a pre-existing pool of granzyme B and perforin mRNAs Immunity 2007 26 6 798 811 (Pubitemid 46907665)
21. Martn-Fontecha A., Thomsen L. L., Brett S., Gerard C., Lipp M., Lanzavecchia A., Sallusto F., Induced recruitment of NK cells to lymph nodes provides IFN- for TH1 priming Nature Immunology 2004 5 12 1260 1265 (Pubitemid 41057741)
22. Savage P. B., Teyton L., Bendelac A., Glycolipids for natural killer T cells Chemical Society Reviews 2006 35 9 771 779 (Pubitemid 44286272)
23. Nakagawa R., Nagafune I., Tazunoki Y., Ehara H., Tomura H., Iijima R., Motoki K., Kamishohara M., Seki S., Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by -galactosylceramide in mice Journal of Immunology 2001 166 11 6578 6584 (Pubitemid 32467197)
24. Nieda M., Nicol A., Koezuka Y., Kikuchi A., Lapteva N., Tanaka Y., Tokunaga K., Suzuki K., Kayagaki N., Yagita H., Hirai H., Juji T., TRAIL expression by activated human CD4 + V 24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells Blood 2001 97 7 2067 2074 (Pubitemid 32239088)
25. Ribas A., Butterfield L. H., Glaspy J. A., Economou J. S., Current developments in cancer vaccines and cellular immunotherapy Journal of Clinical Oncology 2003 21 12 2415 2432 (Pubitemid 46621880)
26. Dredge K., Marriott B. J., Todryk S. M., Dalgleish A. G., Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy Cancer Immunology, Immunotherapy 2002 51 10 521 531 (Pubitemid 35232001)
27. Hirschowitz E. A., Hiestand D. M., Yannelli J. R., Vaccines for lung cancer Journal of Thoracic Oncology 2006 1 1 93 104 (Pubitemid 47164029)
28. Bhattacharya-Chatterjee M., Chatterjee S. K., Foon K. A., The anti-idiotype vaccines for immunotherapy Current Opinion in Molecular Therapeutics 2001 3 1 63 69 (Pubitemid 32177971)
29. Ding L., Lalani E. N., Reddish M., Koganty R., Wong T., Samuel J., Yacyshyn M. B., Meikle A., Fung P. Y. S., Taylor-Papadimitriou J., Longenecker B. M., Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene Cancer Immunology Immunotherapy 1993 36 1 9 17
30. Butts C., Murray N., Maksymiuk A., Goss G., Marshall E., Soulires D., Cormier Y., Ellis P., Price A., Sawhney R., Davis M., Mansi J., Smith C., Vergidis D., Ellis P., MacNeil M., Palmer M., Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer Journal of Clinical Oncology 2005 23 27 6674 6681 (Pubitemid 46190262)
31. Sato S., Noguchi Y., Wada H., Fujita S., Nakamura S., Tanaka R., Nakada T., Hasegawa K., Nakagawa K., Koizumi F., Ono T., Nouso K., Jungbluth A., Chen Y. T., Old L. J., Shiratori Y., Nakayama E., Quantitative real-time RT-PCR analysis of NY-ESO-1 and LAGE-1a mRNA expression in normal tissues and tumors, and correlation of the protein expression with the mRNA copy number International Journal of Oncology 2005 26 1 57 63
32. Jungbluth A. A., Silva W. A. Jr., Iversen K., Frosina D., Zaidi B., Coplan K., Eastlake-Wade S. K., Castelli S. B., Spagnoli G. C., Old L. J., Vogel M., Expression of cancer-testis (CT) antigens in placenta Cancer Immunity 2007 7 15
33. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van Den Eynde B., Knuth A., Boon T., A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma Science 1991 254 5038 1643 1647 (Pubitemid 21917508)
34. Peled N., Oton A. B., Hirsch F. R., Bunn P., MAGE A3 antigen-specific cancer immunotherapeutic Immunotherapy 2009 1 1 19 25
35. Mizukami Y., Kono K., Daigo Y., Takano A., Tsunoda T., Kawaguchi Y., Nakamura Y., Fujii H., Detection of novel cancer-testis antigen-specific T-cell responses in TIL, regional lymph nodes, and PBL in patients with esophageal squamous cell carcinoma Cancer Science 2008 99 7 1448 1454 (Pubitemid 351761737)
36. Kono K., Mizukami Y., Daigo Y., Takano A., Masuda K., Yoshida K., Tsunoda T., Kawaguchi Y., Nakamura Y., Fujii H., Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer Cancer Science 2009 100 8 1502 1509
37. Gonzalez G., Crombet T., Torres F., Catala M., Alfonso L., Osorio M., Neninger E., Garcia B., Mulet A., Perez R., Lage R., Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy Annals of Oncology 2003 14 3 461 466 (Pubitemid 36367426)
38. Garcia Verdecia B., Neninger E., De La Torre A., Leonard I., Martnez R., Viada C., Gonzlez G., Mazorra Z., Lage A., Crombet T., Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine Clinical Cancer Research 2008 14 3 840 846 (Pubitemid 351231168)
39. Vinageras E. N., e La Torre A., Rodrguez M. O., Ferrer M. C., Bravo I., Del Pino M. M., Abreu D. A., Brooks S. A., Rives R., Carrillo C. D.C., Dueas M. G., Viada C., Verdecia B. G., Ramos T. C., Marinello G. G., Dvila A. L., Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer Journal of Clinical Oncology 2008 26 9 1452 1458
40. Giaccone G., Debruyne C., Felip E., Chapman P. B., Grant S. C., Millward M., Thiberville L., D'Addario G., Coens C., Rome L. S., Zatloukal P., Masso O., Legrand C., Phase III study of adjuvant vaccination with Bec2/bacille calmette-guerin in responding patients with limited-disease small-cell lung cancer (European organisation for research and treatment of cancer 08971-08971B; silva study) Journal of Clinical Oncology 2005 23 28 6854 6864
41. Schmitt A., Barth T. F. E., Beyer E., Borchert F., Rojewski M., Chen J., Guillaume P., Gronau S., Greiner J., Mller P., Riechelman H., Schmitt M., The tumor antigens RHAMM and G250/CAIX are expressed in head and neck squamous cell carcinomas and elicit specific CD8 + T cell responses International Journal of Oncology 2009 34 3 629 639
42. Chen X. M., Xu X. Q., Sun K., Hallett W. H. D., Zhao J. D., Zhang D. L., NKG2D ligands expression and NKG2D-mediated cytotoxicity in human laryngeal squamous carcinoma cells Scandinavian Journal of Immunology 2008 67 5 441 447 (Pubitemid 351519387)
43. Liu C. J., Lui M. T., Chen H. L., Lin S. C., Chang K. W., MICA and MICB overexpression in oral squamous cell carcinoma Journal of Oral Pathology Medicine 2007 36 1 43 47
44. Pashine A., Valiante N. M., Ulmer J. B., Targeting the innate immune response with improved vaccine adjuvants Nature Medicine 2005 11 4, supplement S63 S68
45. Cranmer L. D., Trevor K. T., Hersh E. M., Clinical applications of dendritic cell vaccination in the treatment of cancer Cancer Immunology, Immunotherapy 2004 53 4 275 306 (Pubitemid 38392306)
46. Krieg A. M., Toll-like receptor 9 (TLR9) agonists in the treatment of cancer Oncogene 2008 27 2 161 167
47. Corti A., Giovannini M., Belli C., Villa E., Immunomodulatory agents with antivascular activity in the treatment of non-small cell lung cancer: focus on TLR9 agonists, IMiDs and NGR-TNF Journal of Oncology 2010 2010
48. Smyth M. J., Cretney E., Kershaw M. H., Hayakawa Y., Cytokines in cancer immunity and immunotherapy Immunological Reviews 2004 202 275 293 (Pubitemid 39576919)
49. Cross D., Burmester J. K., Gene therapy for cancer treatment: past, present and future Clinical Medicine and Research 2006 4 3 218 227 (Pubitemid 44496015)
50. Salgia R., Lynch T., Skarin A., Lucca J., Lynch C., Jung K., Hodi F. S., Jaklitsch M., Mentzer S., Swanson S., Lukanich J., Bueno R., Wain J., Mathisen D., Wright C., Fidias P., Donahue D., Clift S., Hardy S., Neuberg D., Mulligan R., Webb I., Sugarbaker D., Mihm M., Dranoff G., Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma Journal of Clinical Oncology 2003 21 4 624 630 (Pubitemid 46621895)
51. Nemunaitis J., Sterman D., Jablons D., Smith J. W., Fox B., Maples P., Hamilton S., Borellini F., Lin A., Morali S., Hege K., Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer Journal of the National Cancer Institute 2004 96 4 326 331 (Pubitemid 38256277)
52. Ho M. Y., Sun G. H., Leu S. J. J., Ka S. M., Tang S. J., Sun K. H., Combination of FasL and GM-CSF confers synergistic antitumor immunity in an in vivo model of the murine Lewis lung carcinoma International Journal of Cancer 2008 123 1 123 133
53. Sandler A. B., Dubinett S. M., COX-2 inhibition and lung cancer Seminars in Oncology 2004 31 7, supplement 45 52 (Pubitemid 38879414)
54. Bartlett J. B., Dredge K., Dalgleish A. G., The evolution of thalidomide and its IMiD derivatives as anticancer agents Nature Reviews Cancer 2004 4 4 314 322 (Pubitemid 38525287)
55. Emens L. A., Jaffee E. M., Leveraging the activity of tumor vaccines with cytotoxic chemotherapy Cancer Research 2005 65 18 8059 8064 (Pubitemid 41330564)
56. Nowak A. K., Lake R. A., Robinson B. W. S., Combined chemoimmunotherapy of solid tumours: improving vaccines? Advanced Drug Delivery Reviews 2006 58 8 975 990 (Pubitemid 44780907)
57. Sinkovics J. G., Horvath J. C., Evidence accumulating in support of cancer vaccines combined with chemotherapy: a pragmatic review of past and present efforts International Journal of Oncology 2006 29 4 765 777
58. Gulley J. L., Madan R. A., Arlen P. M., Enhancing efficacy of therapeutic vaccinations by combination with other modalities Vaccine 2007 25 2 B89 B96
59. Zitvogel L., Apetoh L., Ghiringhelli F., Kroemer G., Immunological aspects of cancer chemotherapy Nature Reviews Immunology 2008 8 1 59 73
60. Beyer M., Kochanek M., Darabi K., Popov A., Jensen M., Endl E., Knolle P. A., Thomas R. K., Von Bergwelt-Baildon M., Debey S., Hallek M., Schultze J. L., Reduced frequencies and suppressive function of CD4 + CD25 hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine Blood 2005 106 6 2018 2025 (Pubitemid 41291715)
61. Subbaramaiah K., Dannenberg A. J., Cyclooxygenase 2: a molecular target for cancer prevention and treatment Trends in Pharmacological Sciences 2003 24 2 96 102 (Pubitemid 36135884)
62. Tang S. J., Ho M. Y., Cho H. C., Lin Y. C., Sun G. H., Chi K. H., Wang Y. S., Jhou R. S., Yang W., Sun K. H., Phosphoglycerate kinase 1-overexpressing lung cancer cells reduce cyclooxygenase 2 expression and promote anti-tumor immunity in vivo International Journal of Cancer 2008 123 12 2840 2848
63. Ho M., Tang S., Ng W. V., Yang W., Leu S. J., Lin Y., Feng C., Sung J., Sun K., Nucleotide-binding domain of phosphoglycerate kinase 1 reduces tumor growth by suppressing COX-2 expression Cancer Science 2010 101 11 2411 2416
64. Ho M. Y., Leu S. J. J., Sun G. H., Tao M. H., Tang S. J., Sun K. H., IL-27 directly restrains lung tumorigenicity by suppressing cyclooxygenase-2- mediated activities Journal of Immunology 2009 183 10 6217 6226
65. Yasumoto K., Hanagiri T., Takenoyama M., Lung cancer-associated tumor antigens and the present status of immunotherapy against non-small-cell lung cancer General Thoracic and Cardiovascular Surgery 2009 57 9 449 457
66. So T., Takenoyama M., Mizukami M., Ichiki Y., Sugaya M., Hanagiri T., Sugio K., Yasumoto K., Haplotype loss of HLA class I antigen as an escape mechanism from immune attack in lung cancer Cancer Research 2005 65 13 5945 5952 (Pubitemid 40911201)
67. Baba T., Hanagiri T., Ichiki Y., Kuroda K., Shigematsu Y., Mizukami M., Sugaya M., Takenoyama M., Sugio K., Yasumoto K., Lack and restoration of sensitivity of lung cancer cells to cellular attack with special reference to expression of human leukocyte antigen class I and/or major histocompatibility complex class I chain related molecules A/B Cancer Science 2007 98 11 1795 1802 (Pubitemid 47487918)
68. Ramnath N., Tan D., Li Q., Hylander B. L., Bogner P., Ryes L., Ferrone S., Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival? Cancer Immunology, Immunotherapy 2006 55 8 891 899 (Pubitemid 43673578)
69. Kikuchi E., Yamazaki K., Torigoe T., Cho Y., Miyamoto M., Oizumi S., Hommura F., Dosaka-Akita H., Nishimura M., HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer Cancer Science 2007 98 9 1424 1430 (Pubitemid 47243535)
70. Sigalotti L., Coral S., Fratta E., Lamaj E., Danielli R., Di Giacomo A. M., Altomonte M., Maio M., Epigenetic modulation of solid tumors as a novel approach for cancer immunotherapy Seminars in Oncology 2005 32 5 473 478 (Pubitemid 41396424)
71. Fukuyama T., Ichiki Y., Yamada S., Shigematsu Y., Baba T., Nagata Y., Mizukami M., Sugaya M., Takenoyama M., Hanagiri T., Sugio K., Yasumoto K., Cytokine production of lung cancer cell lines: correlation between their production and the inflammatory/immunological responses both in vivo and in vitro Cancer Science 2007 98 7 1048 1054 (Pubitemid 46865390)
72. Karanikas V., Zamanakou M., Kerenidi T., Dahabreh J., Hevas A., Nakou M., Gourgoulianis K. I., Germenis A. E., Indoleamine 2,3-dioxygenase (IDO) expression in lung cancer Cancer Biology Therapy 2007 6 8 1258 1262 (Pubitemid 351590380)
73. Rodriguez P. C., Quiceno D. G., Zabaleta J., Ortiz B., Zea A. H., Piazuelo M. B., Delgado A., Correa P., Brayer J., Sotomayor E. M., Antonia S., Ochoa J. B., Ochoa A. C., Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses Cancer Research 2004 64 16 5839 5849 (Pubitemid 39095585)
74. Groh V., Wu J., Yee C., Spies T., Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation Nature 2002 419 6908 734 738 (Pubitemid 35177960)
75. Zang X., Allison J. P., The B7 family and cancer therapy: costimulation and coinhibition Clinical Cancer Research 2007 13 18 5271 5279 (Pubitemid 47510350)
76. Konishi J., Yamazaki K., Azuma M., Kinoshita I., Dosaka-Akita H., Nishimura M., B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression Clinical Cancer Research 2004 10 15 5094 5100 (Pubitemid 39106851)
77. Viard-Leveugle I., Veyrenc S., French L. E., Brambilla C., Brambilla E., Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma Journal of Pathology 2003 201 2 268 277 (Pubitemid 37258938)
78. Witz I. P., Yin-Yang activities and vicious cycles in the tumor microenvironment Cancer Research 2008 68 1 9 13 (Pubitemid 351380098)
79. Lechner M. G., Liebertz D. J., Epstein A. L., Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells Journal of Immunology 2010 185 4 2273 2284
80. Ben-Baruch A., Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators Seminars in Cancer Biology 2006 16 1 38 52 (Pubitemid 43139708)
81. Serafini P., Borrello I., Bronte V., Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression Seminars in Cancer Biology 2006 16 1 53 65 (Pubitemid 43139709)
82. Kusmartsev S., Gabrilovich D. I., Role of immature myeloid cells in mechanisms of immune evasion in cancer Cancer Immunology, Immunotherapy 2006 55 3 237 245 (Pubitemid 41683212)
83. Nagaraj S., Gupta K., Pisarev V., Kinarsky L., Sherman S., Kang L., Herber D. L., Schneck J., Gabrilovich D. I., Altered recognition of antigen is a mechanism of CD8 + T cell tolerance in cancer Nature Medicine 2007 13 7 828 835 (Pubitemid 47038194)
84. Maile R., Siler C. A., Kerry S. E., Midkiff K. E., Collins E. J., Frelinger J. A., Peripheral CD8 tuning dynamically modulates the size and responsiveness of an antigen-specific T cell pool in vivo Journal of Immunology 2005 174 2 619 627 (Pubitemid 40094253)
85. Kusmartsev S., Nagaraj S., Gabrilovich D. I., Tumor-associated CD8 + T cell tolerance induced by bone marrow-derived immature myeloid cells Journal of Immunology 2005 175 7 4583 4592 (Pubitemid 41361997)
86. Bronte V., Zanovello P., Regulation of immune responses by L-arginine metabolism Nature Reviews Immunology 2005 5 8 641 654 (Pubitemid 41113195)
87. Chiou S. H., Sheu B. C., Chang W. C., Huang S. C., Hong-Nerng H., Current concepts of tumor-infiltrating lymphocytes in human malignancies Journal of Reproductive Immunology 2005 67 1-2 35 50 (Pubitemid 41415554)
88. Coussens L. M., Werb Z., Inflammation and cancer Nature 2002 420 6917 860 867 (Pubitemid 36019639)
89. Allavena P., Sica A., Solinas G., Porta C., Mantovani A., The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages Critical Reviews in Oncology/Hematology 2008 66 1 1 9 (Pubitemid 351324128)
90. Lewis C. E., Pollard J. W., Distinct role of macrophages in different tumor microenvironments Cancer Research 2006 66 2 605 612 (Pubitemid 43165918)
91. Ma J., Liu L., Che G., Yu N., Dai F., You Z., The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time BMC Cancer 2010 10, article no. 112
92. Biswas S. K., Sica A., Lewis C. E., Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms Journal of Immunology 2008 180 4 2011 2017
93. Solinas G., Germano G., Mantovani A., Allavena P., Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation Journal of Leukocyte Biology 2009 86 5 1065 1073
94. Woo E. Y., Chu C. S., Goletz T. J., Schlienger K., Yeh H., Coukos G., Rubin S. C., Kaiser L. R., June C. H., Regulatory CD4 + CD25 + T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer Cancer Research 2001 61 12 4766 4772 (Pubitemid 32691889)
95. Ishida T., Ishii T., Inagaki A., Yano H., Komatsu H., Iida S., Inagaki H., Ueda R., Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege Cancer Research 2006 66 11 5716 5722 (Pubitemid 43927124)
96. Woo E. Y., Yeh H., Chu C. S., Schlienger K., Carroll R. G., Riley J. L., Kaiser L. R., June C. H., Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation Journal of Immunology 2002 168 9 4272 4276 (Pubitemid 34441324)
97. Larmonier N., Marron M., Zeng Y., Cantrell J., Romanoski A., Sepassi M., Thompson S., Chen X., Andreansky S., Katsanis E., Tumor-derived CD4 + CD25 + regulatory T cell suppression of dendritic cell function involves TGF- and IL-10 Cancer Immunology, Immunotherapy 2007 56 1 48 59 (Pubitemid 44812446)
98. Sato E., Olson S. H., Ahn J., Bundy B., Nishikawa H., Qian F., Jungbluth A. A., Frosina D., Gnjatic S., Ambrosone C., Kepner J., Odunsi T., Ritter G., Lele S., Chen Y. T., Ohtani H., Old L. J., Odunsi K., Intraepithelial CD8 + tumor-infiltrating lymphocytes and a high CD8 + /regulatory T cell ratio are associated with favorable prognosis in ovarian cancer Proceedings of the National Academy of Sciences of the United States of America 2005 102 51 18538 18543 (Pubitemid 43011261)
99. Nishikawa H., Sakaguchi S., Regulatory T cells in tumor immunity International Journal of Cancer 2010 127 4 759 767
100. Tanaka H., Tanaka J., Kjaergaard Jo. J.., Shu S., Depletion of CD4 + CD25 + regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes Journal of Immunotherapy 2002 25 3 207 217 (Pubitemid 34533310)
101. Dannull J., Su Z., Rizzieri D., Yang B. K., Coleman D., Yancey D., Zhang A., Dahm P., Chao N., Gilboa E., Vieweg J., Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells Journal of Clinical Investigation 2005 115 12 3623 3633 (Pubitemid 43121851)